专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO2010051064A1 COMPOUNDS THAT INHIBIT NFκB ACTIVITY 审中-公开
标题翻译：禁止NF？B活性的化合物
公开(公告)号：WO2010051064A1
公开(公告)日：2010-05-06
申请号：PCT/US2009/043011
申请日：2009-05-06
申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK , LANDRY, Donald, W. , KIM, Tae-Wan , DENG, Shi-Xian , GONG, Gangli , HWANG, Jeremy, C. , XIE, Yuli , LIU, Yidong , RINDERSPACHER, Alison
发明人： LANDRY, Donald, W. , KIM, Tae-Wan , DENG, Shi-Xian , GONG, Gangli , HWANG, Jeremy, C. , XIE, Yuli , LIU, Yidong , RINDERSPACHER, Alison
IPC分类号： A01N43/42 , A61K31/47
CPC分类号： C07D215/40 , A61K31/47 , C07D401/12 , C07D409/12
摘要： The present invention relates to compounds with activity as BACE1 and NFκB modulators, and methods for treating, preventing, or ameliorating neurodegenerative diseases, such as Alzheimer's disease. The present invention is also directed to the treatment of diseases related to dysfunction of cell proliferation, the immune system and/or inflammation using such compounds or pharmaceutical compositions containing such candidate compounds.
摘要翻译：本发明涉及具有作为BACE1和NFκB调节剂活性的化合物，以及治疗，预防或改善神经变性疾病如阿尔茨海默氏病的方法。本发明还涉及使用这些化合物或包含这些候选化合物的药物组合物治疗与细胞增殖功能障碍，免疫系统和/或炎症有关的疾病。

22. 发明申请

WO2009070688A1 METHODS, SYSTEMS, AND MEDIA FOR CONTROLLING ACCESS TO APPLICATIONS ON MOBILE DEVICES 审中-公开
标题翻译：控制移动设备应用的方法，系统和媒体
公开(公告)号：WO2009070688A1
公开(公告)日：2009-06-04
申请号：PCT/US2008/084885
申请日：2008-11-26
申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK , LANDRY, Donald, W. , FAUX, Tyler , GASPERETTI, Joseph
发明人： LANDRY, Donald, W. , FAUX, Tyler , GASPERETTI, Joseph
IPC分类号： G06F15/173
CPC分类号： G09B23/28 , G09B7/00
摘要： Methods, systems, and media for controlling access to applications on mobile devices are provided. In accordance with some embodiments, a method for controlling access to mobile device applications is provided, the method comprising: receiving a presentation for distribution to a plurality of mobile devices, wherein at least one task is associated with the presentation and control information for controlling access to applications installed on each of the plurality of mobile devices is associated with the presentation; transmitting the presentation to the plurality of mobile devices; determining whether each of the plurality of mobile devices performed the at least one task associated with the presentation; and, in response to determining that a mobile device has not performed the at least one task, using the control information to disable at least one application installed on the mobile device.
摘要翻译：提供了用于控制对移动设备上的应用程序的访问的方法，系统和媒体。根据一些实施例，提供了一种用于控制对移动设备应用的访问的方法，所述方法包括：接收用于分发给多个移动设备的呈现，其中至少一个任务与所述呈现和用于控制访问的控制信息相关联安装在所述多个移动设备中的每一个上的应用与所述呈现相关联; 将所述呈现发送到所述多个移动设备; 确定所述多个移动设备中的每一个是否执行与所述呈现相关联的所述至少一个任务; 并且响应于确定移动设备尚未执行所述至少一个任务，使用所述控制信息来禁用安装在所述移动设备上的至少一个应用。

23. 发明申请

WO2007095586A3 NEURONAL PAIN PATHWAY MODULATORS 审中-公开
标题翻译：神经痛路径调制器
公开(公告)号：WO2007095586A3
公开(公告)日：2008-03-13
申请号：PCT/US2007062154
申请日：2007-02-14
申请人： UNIV COLUMBIA , AMBRON RICHARD , SUNG YING-JU , GREENWOOD JEREMY , FRYE LEAH , DENG SHI-XIAN , XIE YULI , LANDRY DONALD W
发明人： AMBRON RICHARD , SUNG YING-JU , GREENWOOD JEREMY , FRYE LEAH , DENG SHI-XIAN , XIE YULI , LANDRY DONALD W
IPC分类号： A01N43/02 , A61K31/335
CPC分类号： A61K31/40 , A61K31/235 , A61K31/335
摘要： The present invention relates to compounds that may be used to inhibit activation of protein kinase G ("PKG"). It is based, at least in part, on the discovery of the tertiary structure of PKG and the identification of molecules that either bind to the active site of PKG and/or are analogs of balanol.
摘要翻译：本发明涉及可用于抑制蛋白激酶G（“PKG”）活化的化合物。至少部分基于PKG的三级结构的发现以及与PKG的活性位点结合的分子的鉴定和/或是平衡醇的类似物。

24. 发明申请

WO2006101497A3 NOVEL ANTI-ARRYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RYR2) 审中-公开
标题翻译：靶向雷诺星受体（RYR2）的新型抗ARRYTHMIC和心脏衰竭药物
公开(公告)号：WO2006101497A3
公开(公告)日：2007-08-02
申请号：PCT/US2005010056
申请日：2005-03-24
申请人： UNIV COLUMBIA , MARKS ANDREW R , LANDRY DONALD W , DENG SHIXIAN , CHENG ZHEN ZHUANG
发明人： MARKS ANDREW R , LANDRY DONALD W , DENG SHIXIAN , CHENG ZHEN ZHUANG
IPC分类号： G01N33/53 , G01N33/567
CPC分类号： G01N33/6887 , G01N2800/325 , G01N2800/326
摘要： The present invention provides novel 1,4-benzothiazepine intermediates and derivatives, methods for synthesizing same, and methods for assaying same. The present invention also provides methods for using these novel compounds to limit or prevent a decrease in the level of RyR2-bound FKBP12.6 in a subject; to prevent exercise-induced sudden cardiac death in a subject; and to treat or prevent heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia in a subject. The present invention further provides methods for identifying an agent that enhances binding of RyR2 and FKBP12.6, and agents identified by these methods. Additionally, the present invention provides methods for identifying agents for use in treating or preventing heart failure, atrial fibrillation, or exerciseinduced cardiac arrhythmia, and in preventing exercise-induced sudden cardiac death. Also provided are agents identified by such methods.
摘要翻译：本发明提供新的1,4-苯并硫氮杂中间体及其衍生物，其合成方法及其测定方法。本发明还提供了使用这些新化合物来限制或防止受试者中RyR2结合的FKBP12.6水平降低的方法; 以防止受试者运动性心源性猝死; 并且治疗或预防受试者的心力衰竭，心房颤动或运动引起的心律失常。本发明还提供用于鉴定增强RyR2和FKBP12.6的结合的试剂以及通过这些方法鉴定的试剂的方法。此外，本发明提供了用于鉴定用于治疗或预防心力衰竭，心房颤动或运动性心律失常以及预防运动性心源性猝死的药剂的方法。还提供了通过这种方法鉴定的药剂。

25. 发明申请

WO2006101497A2 NOVEL ANTI-ARRYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RYR2) 审中-公开
标题翻译：靶向雷诺星受体（RYR2）的新型抗ARRYTHMIC和心脏衰竭药物
公开(公告)号：WO2006101497A2
公开(公告)日：2006-09-28
申请号：PCT/US2005/010056
申请日：2005-03-24
申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK , MARKS, Andrew, R. , LANDRY, Donald, W. , DENG, Shixian , CHENG, Zhen, Zhuang
发明人： MARKS, Andrew, R. , LANDRY, Donald, W. , DENG, Shixian , CHENG, Zhen, Zhuang
IPC分类号： G01N33/53 , G01N33/567
CPC分类号： G01N33/6887 , G01N2800/325 , G01N2800/326
摘要： The present invention provides novel 1,4-benzothiazepine intermediates and derivatives, methods for synthesizing same, and methods for assaying same. The present invention also provides methods for using these novel compounds to limit or prevent a decrease in the level of RyR2-bound FKBP12.6 in a subject; to prevent exercise-induced sudden cardiac death in a subject; and to treat or prevent heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia in a subject. The present invention further provides methods for identifying an agent that enhances binding of RyR2 and FKBP12.6, and agents identified by these methods. Additionally, the present invention provides methods for identifying agents for use in treating or preventing heart failure, atrial fibrillation, or exerciseinduced cardiac arrhythmia, and in preventing exercise-induced sudden cardiac death. Also provided are agents identified by such methods.
摘要翻译：本发明提供新的1,4-苯并硫氮杂中间体及其衍生物，其合成方法及其测定方法。本发明还提供了使用这些新化合物来限制或防止受试者中RyR2结合的FKBP12.6水平降低的方法; 以防止受试者运动性心源性猝死; 并且治疗或预防受试者的心力衰竭，心房颤动或运动引起的心律失常。本发明还提供用于鉴定增强RyR2和FKBP12.6的结合的试剂以及通过这些方法鉴定的试剂的方法。另外，本发明提供了用于鉴定用于治疗或预防心力衰竭，心房颤动或运动心律失常以及预防运动性心源性猝死的药剂的方法。还提供了通过这种方法鉴定的药剂。

26. 发明申请

WO2004075783A3 A METHOD FOR STABILIZING BLOOD PRESSURE IN HEMODIALYSIS SUBJECTS 审中-公开
标题翻译：一种用于稳定血液透析患者血液压力的方法
公开(公告)号：WO2004075783A3
公开(公告)日：2004-12-29
申请号：PCT/US2004006029
申请日：2004-02-26
申请人： LANDRY DONALD W , OLIVER JUAN A
发明人： LANDRY DONALD W , OLIVER JUAN A
IPC分类号： A61F20060101 , A61K38/11 , A61K38/17
CPC分类号： A61K38/11
摘要： The present invention provides a method for regulating blood pressure in a hemodialysis subject using a vasopressin receptor agonist, so as to facilitate removal of excessive extracellular fluid in the subject.

27. 发明申请

WO1993020076A1 CATALYTIC ANTIBODIES AGAINST COCAINE AND METHODS OF USING AND PRODUCING SAME 审中-公开
标题翻译：抗COCAINE的催化抗体及其使用和生产方法
公开(公告)号：WO1993020076A1
公开(公告)日：1993-10-14
申请号：PCT/US1993003163
申请日：1993-04-02
申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY ... , LANDRY, Donald, W. , ZHAO, Kang
发明人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY ...
IPC分类号： C07D471/04
CPC分类号： C07D451/02 , A61K38/00 , A61K47/6803 , C07F9/6561 , C07F9/657172 , C07F9/6584 , C07K16/44 , C12N9/0002
摘要： This invention provides compounds which are analogs to the hydrolysis transition-state of a cocaine benzoyl ester group. This invention also provides such analogs linked to carrier proteins, and antibodies thereto. This invention further provides pharmaceutical composition for decreasing cocaine concentration in a subject using the antibodies produced.
摘要翻译：本发明提供了类似于可卡因苯甲酰酯基的水解转变状态的化合物。本发明还提供了与载体蛋白质及其抗体连接的类似物。本发明还提供了使用所产生抗体降低受试者中可卡因浓度的药物组合物。

28. 发明申请

WO2012122534A3 N-QUINOLIN-BENZENSULFONAMIDES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER, AUTOIMMUNE DISORDERS AND INFLAMMATION 审中-公开
标题翻译：用于治疗癌症，自身免疫性疾病和炎症的N-喹啉宁 - 苯并呋喃和相关化合物
公开(公告)号：WO2012122534A3
公开(公告)日：2014-04-24
申请号：PCT/US2012028619
申请日：2012-03-09
申请人： UNIV COLUMBIA , LANDRY DONALD W , O'CONNOR OWEN , DENG SHI-XIAN , KALAC MATKO , RINDERSPACHER K ALISON
发明人： LANDRY DONALD W , O'CONNOR OWEN , DENG SHI-XIAN , KALAC MATKO , RINDERSPACHER K ALISON
IPC分类号： A61K31/535
CPC分类号： C07D215/40 , A61K31/47 , A61K31/4709 , C07D409/12
摘要： The present invention relates to the NQBS class of molecules. It is based, at least in part, on the discovery that a representative group of compounds have been observed to inhibit nuclear translocation of NF-&kgr;&Bgr; subunits. Without being bound by any particular theory, this inhibition of nuclear translocation may be mediated by either (i) binding of the NQBS or related compound to the C-terminus of the RHD, which specifically mediates the nuclear internalization; or (ii) NQBS-mediated stabilization of the dimer/&Igr;&kgr;&Bgr; complex, disallowing dissociation of the active NF~KB monomers, and thus, inhibiting the generation of the subunits necessary to enter the nucleus. The NQBS class of molecules, and related molecules, may be used in therapeutic applications where inhibition of NF-&kgr;&Bgr; translocation is beneficial, including but not limited to the treatment of cancer, autoimmune disorders, and inflammatory states.
摘要翻译：本发明涉及NQBS类分子。至少部分地基于这样的发现：已经观察到代表性的一组化合物抑制NF-κB和Bgr的核易位; 亚基。不受任何特定理论的约束，这种核易位的抑制可以由（i）NQBS或相关化合物与RHD的C-末端结合而介导，其特异性介导核内在化; 或（ii）NQBS介导的二聚体稳定化＆amp; 复合物，不允许活性NF-κB单体的解离，从而抑制进入细胞核所必需的亚基的产生。 NQBS分子类和相关分子可用于治疗应用，其中抑制NF-和kgr; Bgr; 易位是有益的，包括但不限于治疗癌症，自身免疫性疾病和炎症状态。

29. 发明申请

WO2013166040A1 S-FTA AND S-FTA ANALOGUES CAPABLE OF INHIBITING RETINOL-DEPENDENT RBP4-TTR INTERACTION FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION, STARGARDT DISEASE, AND OTHER RETINAL DISEASE CHARACTERIZED BY EXCESSIVE LIPOFUSCIN ACCUMULATION 审中-公开
标题翻译： S-FTA和S-FTA类似物可以抑制依赖性依赖性的RBP4-TTR相互作用治疗老年相关性变性，星形胶质细胞病变和其他由过度LIPOFUSCIN积累表现的细胞毒性疾病
公开(公告)号：WO2013166040A1
公开(公告)日：2013-11-07
申请号：PCT/US2013/038908
申请日：2013-04-30
申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK , PETRUKHIN, Konstantin , DOBRI, Nicoleta , LANDRY, Donald, W.
发明人： PETRUKHIN, Konstantin , DOBRI, Nicoleta , LANDRY, Donald, W.
IPC分类号： A61K31/19
CPC分类号： A61K31/202 , A61K31/232
摘要： A method for treating a disease characterized, by excessive lipofuscin accumulation in the retina in a mammal afflicted therewith comprising administering to the mammal an effective amount of a compound having the structure (I), wherein X is O or S, or an ester or a pharmaceutically acceptable salt thereof.
摘要翻译：一种用于治疗疾病的方法，其特征在于，在患有其的哺乳动物中视网膜中过度的脂褐素积累，包括给予哺乳动物有效量的具有结构（I）的化合物，其中X为O或S，或酯或其药学上可接受的盐。

30. 发明申请

WO2012122534A2 N-QUINOLIN-BENZENSULFONAMIDES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER, AUTOIMMUNE DISORDERS AND INFLAMMATION 审中-公开
标题翻译：用于治疗癌症，自身免疫性疾病和炎症的N-喹啉宁 - 苯二甲酰亚胺和相关化合物
公开(公告)号：WO2012122534A2
公开(公告)日：2012-09-13
申请号：PCT/US2012/028619
申请日：2012-03-09
申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK , LANDRY, Donald, W. , O'CONNOR, Owen , DENG, Shi-Xian , KALAC, Matko , RINDERSPACHER, K., Alison
发明人： LANDRY, Donald, W. , O'CONNOR, Owen , DENG, Shi-Xian , KALAC, Matko , RINDERSPACHER, K., Alison
IPC分类号： A23C3/02
CPC分类号： C07D215/40 , A61K31/47 , A61K31/4709 , C07D409/12
摘要： The present invention relates to the NQBS class of molecules. It is based, at least in part, on the discovery that a representative group of compounds have been observed to inhibit nuclear translocation of NF-κΒ subunits. Without being bound by any particular theory, this inhibition of nuclear translocation may be mediated by either (i) binding of the NQBS or related compound to the C-terminus of the RHD, which specifically mediates the nuclear internalization; or (ii) NQBS-mediated stabilization of the dimer/ΙκΒ complex, disallowing dissociation of the active NF~KB monomers, and thus, inhibiting the generation of the subunits necessary to enter the nucleus. The NQBS class of molecules, and related molecules, may be used in therapeutic applications where inhibition of NF-κΒ translocation is beneficial, including but not limited to the treatment of cancer, autoimmune disorders, and inflammatory states.
摘要翻译：本发明涉及NQBS类分子。至少部分基于以下发现：已经观察到代表性的一组化合物抑制NF-κB的核易位。亚基。不受任何特定理论的约束，这种核易位的抑制可以由（i）NQBS或相关化合物与RHD的C-末端结合而介导，其特异性介导核内在化; 或（ii）NQBS介导的二聚体稳定化复合物，不允许活性NF-κB单体的解离，从而抑制进入细胞核所必需的亚基的产生。 NQBS分子类和相关分子可用于治疗应用，其中抑制NF- 易位是有益的，包括但不限于治疗癌症，自身免疫性疾病和炎症状态。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式